On October 31, 2023 Kernal Biologics, Inc. (Kernal Bio) — a development-stage mRNA-technology company developing cancer therapeutics designed to improve patients’ survival rate and quality of life — reported that it is presenting a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2023 Annual Meeting on Friday, November 3, 2023 in San Diego, CA (Press release, Kernal Biologics, OCT 31, 2023, View Source [SID1234636579]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The poster presentation features preclinical insights into KR-336, an onco-selective mRNA LNP therapeutic that Kernal Bio has rationally designed using their mRNA2.0 platform to be selectively translated into therapeutic protein within the tumor microenvironment. These data support the feasibility of systemically administering Kernal’s onco-selective mRNA LNP to achieve tumor-localized immunomodulation as a highly efficacious and well tolerated treatment option for patients with otherwise immunosuppressive tumors.
"Previously, we have shown that local onco-selective mRNA LNP therapy via intratumoral injections can result in complete responses in various pre-clinical murine tumor models, including those that are resistant to checkpoint inhibitors," said Kernal Bio Co-founder and Chief Executive Officer Yusuf Erkul, M.D. "At SITC (Free SITC Whitepaper), we look forward to reporting the outcome of in vivo proof-of-concept studies for systemic mRNA LNP administration, which resulted in robust anti-tumor effectiveness."
Details for the Kernal Bio presentation are as follows:
Poster Presentation: Systemically Administered Onco-Selective mRNA LNP Achieves Tumor Regression and Improves Overall Survival, As Monotherapy
Abstract #: 1339
Presenter: Matthew Strout, MD, PhD, Vice President of Business Development, Kernal Biologics
Time: Friday, November 3, 2023, 9:00 AM – 7:00 PM PDT